LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

Strona główna・Stock List・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

38.61 5.09

Buy Sell

Overview

Share price change

24h

Current

Min

36.94

Max

38.98

Key metrics
By Trading Economics
Income	-7.4M -81M
EPS	-0.5
Employees	205
EBITDA	-6.8M -79M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+39.74% upside

Dividends
By Dow Jones
Next Earnings	5 maj 2026

Market Stats
By TradingEconomics
Market Cap	3.4B 5.6B
Previous open	33.52
Previous close	38.61

Technical Score

By Trading Central

Confidence

Bearish Evidence

4.88 / 5.87 Support & Resistance

Cogent Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 lut 2026, 22:36 UTC

Earnings

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 lut 2026, 22:32 UTC

Earnings

Woodside Energy Fiscal Year Net Profit Falls 24%

23 lut 2026, 23:58 UTC

Market Talk

Earnings

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 lut 2026, 23:58 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

23 lut 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 lut 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Crescent Capital Partners Owns 53% of ClearView Wealth

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 lut 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 lut 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 lut 2026, 23:27 UTC

Earnings

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 lut 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 lut 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 lut 2026, 22:31 UTC

Earnings

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 lut 2026, 22:24 UTC

Earnings

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Underlying Ebitda A$700.9 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 lut 2026, 22:20 UTC

Earnings

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Comparison

Price change

Cogent Biosciences Inc Forecast

Price Target

By TipRanks

39.74% upside

12 Months Forecast

Average 52.18 USD 39.74%

High 67 USD

Low 35 USD

Based on 12 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Cogent Biosciences Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.88 / 5.87Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.